CMS-121 Capsules
CMS-121 Capsules USA — Capsules
Fisetin-Derived Research Compound
CMS-121 is a synthetic small molecule derived from the plant flavonoid fisetin, produced for laboratory research use only. It is supplied in capsule form for controlled experimental work and is not intended for any other application.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
CMS-121 is a synthetic small molecule derived from the plant flavonoid fisetin, produced for laboratory research use only. It is supplied in capsule form for controlled experimental work and is not intended for any other application.
The published record specific to CMS-121 is limited. The candidate literature available here addresses acetyl-CoA carboxylase biology, the enzyme family that has been named as a molecular target in work on this chemical series, rather than CMS-121 itself.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for this lot is being finalised and will be published here as soon as the lab returns it.
CMS-121 belongs to a series of synthetic derivatives developed from the flavonoid scaffold of fisetin. Reports associated with this series describe acetyl-CoA carboxylase 1 as the proposed molecular target, placing the compound within research on fatty acid synthesis and lipid metabolic regulation. The molecular profile supplied corresponds to a small molecule of formula C20H19NO3 with a molecular weight of 321.4.
Acetyl-CoA carboxylase enzymes have themselves been examined in experimental systems in relation to lipid accumulation, mitochondrial function, and AMPK-linked signaling, and in endothelial cell models where the phosphorylation state of acetyl-CoA carboxylase 1 has been evaluated. These studies characterise the target pathway rather than CMS-121, and the directly published research record for the compound itself could not be established from the references available.
CMS-121 is described as arising from medicinal chemistry work on fisetin derivatives, in which the flavonoid scaffold was modified to produce synthetic analogues for laboratory evaluation. The specific development program, synthesis route, and initial characterisation of the compound are not documented in the references available here, and no origin account can be stated with confidence.
What can be traced in the available literature is the research history of the proposed target. Acetyl-CoA carboxylase has been studied as a regulatory node in lipid metabolism, including work examining its relationship to AMPK signaling, PPARα, and CPT1A in lipid accumulation models, and work examining regulation of acetyl-CoA carboxylase 1 phosphorylation in endothelial cell systems. The published record connecting CMS-121 directly to these pathways is not represented in the candidate references.
CMS-121 appears in research framed around acetyl-CoA carboxylase and fatty acid synthesis, the pathway named as its proposed target. The literature available here characterises that pathway in experimental systems: lipid accumulation and mitochondrial function in relation to AMPK, PPARα, and CPT1A signaling, and acetyl-CoA carboxylase 1 phosphorylation in endothelial cell models. These frameworks describe target biology and do not constitute a research record for the compound itself, which remains thin in the sources available.
4 of the 5 areas below are addressed directly by a paper cited on this page.
Acetyl-CoA carboxylase target biology
Addressed on this page by Chen 2025. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Chen, T. et al. (2025) — Long noncoding RNA ZRANB2-AS2 promotes endothelial cell dysfunction by inhibiting phosphorylation of acetyl-CoA carboxylase 1 in diabetes
Fatty acid synthesis pathway models
No paper cited on this page reports on fatty, acid or synthesis. This heading marks where CMS-121 Capsules is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
AMPK-linked lipid metabolic signaling
Addressed on this page by Dong 2024. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Dong, J. et al. (2024) — ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK- PPARα- CPT1A axis
Mitochondrial function in lipid accumulation models
Addressed on this page by Dong 2024, Chen 2025. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Dong, J. et al. (2024) — ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK- PPARα- CPT1A axis
- Chen, T. et al. (2025) — Long noncoding RNA ZRANB2-AS2 promotes endothelial cell dysfunction by inhibiting phosphorylation of acetyl-CoA carboxylase 1 in diabetes
Endothelial cell signaling models
Addressed on this page by Chen 2025. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Chen, T. et al. (2025) — Long noncoding RNA ZRANB2-AS2 promotes endothelial cell dysfunction by inhibiting phosphorylation of acetyl-CoA carboxylase 1 in diabetes
The references section of this page cites 2 primary papers published between 2024 and 2025 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
CMS-121 Capsules is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for CMS-121 Capsules, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
CMS-121 Capsules is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under acetyl-CoA carboxylase target biology, fatty acid synthesis pathway models and AMPK-linked lipid metabolic signaling.
The 2 papers cited on this page, published between 2024 and 2025 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented alongside compounds with decades of published research, as though the evidence base is comparable.
It is not. CMS-121 Capsules rests on 2 cited papers (between 2024 and 2025). A record that thin cannot support conclusions about mechanism, effect or safety, and the honest reading is that this compound has been studied very little rather than studied and validated.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of CMS-121 Capsules is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy CMS-121 Capsules in the United States through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Storage
- Cool, dry, away from direct light
- Humidity
- Keep sealed; capsule shells are hygroscopic
- Reconstitution
- Not applicable — supplied pre-measured
- Format
- Oral capsule
CMS-121 Capsules is supplied in capsule form, which removes the reconstitution step entirely: there is no vehicle to add, no reconstitution volume to record and no post-reconstitution stability window to track. What that leaves a laboratory to control is storage — capsule shells draw moisture from the air, so the container should be kept sealed and dry rather than decanted into an open vessel.
Because the material is already at its labelled quantity per capsule, batch verification carries more weight in this format than it does for powder: there is no point at which the researcher independently confirms mass by weighing. The measured content published for each lot is the figure that answers that question.
- 1 × sealed capsule bottle (10mg per capsule / Single Bottle - Pack of 60), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Laboratory consumables of any kind
- Dosing, administration or protocol guidance of any kind
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each capsule contains the labeled quantity of CMS-121. Independent third-party analysis verifies purity, identity, and net content per batch.
The product contains only the compound in capsule form. Any laboratory materials required for sample preparation or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK- PPARα- CPT1A axis
PubMedLong noncoding RNA ZRANB2-AS2 promotes endothelial cell dysfunction by inhibiting phosphorylation of acetyl-CoA carboxylase 1 in diabetes
PubMedRelated
You May Also Like
Methylated Beta-Carboline Alkaloid 9-Me-BC (9-methyl-beta-carboline) is a small methylated beta-carboline alkaloid studied in neurochemical research models. It is supplied in capsule form strictly for laboratory research use.
$64.99
Uncharacterised Research Compound Compound-7P is supplied as capsules for laboratory research use. The designation "Compound-7P" is a non-systematic label and does not correspond to a single identified chemical entity in the published chemical or pharmacological literature. No PubChem record matches the name, and no molecular formula, sequence or structural profile was supplied with it.
$49.99
Redox-Active Flavin Analogue 5-Deazaflavin is a synthetic analogue of the flavin ring system in which the nitrogen at position 5 of the isoalloxazine core is replaced by carbon. The parent heterocycle (C11H7N3O2, MW 213.19) and its substituted derivatives are produced for laboratory research and are handled within controlled experimental environments.
$59.99
Phenothiazinium Redox Dye Methylene blue is a synthetic phenothiazinium salt and redox-active dye with the molecular formula C16H18ClN3S. It is supplied here in capsule form for laboratory research use within controlled experimental settings.
$29.99